Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
PARIS and NEW YORK, March 24, 2016 -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company focused on the development of new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has completed a private placement with U.S. institutional investors totalling €5.54 million. Directly following the U.S. capital increase, the Company raised an additional €3.04 million through a public offering in Europe through existing shareholders, for a total of €8.6 million.
In these two placements, the Company issued 1,429,973 shares at €6.00 per share, and warrants to purchase an additional 714,986 shares at an exercise price of €7.75 per share for 30 months. The warrants, if fully exercised, would generate additional proceeds of €5.5 million. Participation in the European rights offering was open to shareholders of Quantum Genomics as of March 16, 2016.
“This capital increase is consistent with our expansion strategy, which includes the recently announced establishment of a U.S. Clinical Advisory Board and the opening of an office in New York on March 1st, 2016. The funds raised will enable us to further advance, in the U.S. and various European countries, the Phase II clinical trials of our products for the treatment of resistant hypertension and heart failure,” said Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics.
Maxim Group LLC acted as the exclusive placement agent in the United States, and Invest Securities managed the subscriptions in France.
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC). The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
CONTACTS Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77 Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 [email protected] ACTUS finance et communication (Europe) Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 [email protected] The Ruth Group (U.S.) Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592
